Abstract
Drug associated acute pancreatitis is uncommon entity but may arise with high morbidity and mortality. Pancreatitis due to imatinib use is rarely seen in the literature. A 70-year old female patient presented to our clinic with typical abdominal pain for of acute pancreatitis, 3 times higher amylase and lipase values than the upper limits. She had been receiving imatinib treatment for two years for gastrointestinal stromal tumor (GIST). Our case who had no other reason to explain the development of acute pancreatitis is presented because of the rare occurence of pancreatitis due to imatinib use in the literature.
References
- Referanslar:1. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460–6. [PubMed]2. Greenberger NJ, Toskes PP. Acute and chronic pancreatitis. Harrison's Online. Available from:http://www.accessmedicine.com. [accessed on 2006 May 31]3. Chari ST, Vege SS. Etiology of acute pancreatitis. Up-to-date. Available from: http://www.uptodate.com. [accessed on 2006 May 31]4. Hunter TB, Bjelland JC. Gastrointestinal complications of leukemia and its treatment. AJR Am J Roentgenol. 1984;142:513–8. [PubMed]5. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH. Drug-associated acute pancreatitis: Twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol. 1999;94:2417–22. [PubMed]
Abstract
İlaç ilişkili akut pankreatit nadir görülmekle birlikte yüksek morbitite ve mortaliteyle seyredebilir. Literatürde İmatinib kullanımına bağlı gelişen pankreatit olgusuna çok az rastlanmaktadır. Kuşak tarzında akut pankreatit için tipik karın ağrısı, normal üst sınırlardan üç kat yüksek amilaz ve lipaz değerleriyle kliniğimize başvuran yetmiş yaşındaki kadın hasta, gastrointestinal stromal tümör (GİST) nedeniyle iki yıldır imatinib tedavisi almaktaydı. Akut pankreatit gelişimini açıklayacak başka bir neden saptanmayan olgumuz, literatürde İmatinib kullanımına bağlı pankreatite çok ender rastlanması nedeniyle sunulmuştur.
References
- Referanslar:1. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460–6. [PubMed]2. Greenberger NJ, Toskes PP. Acute and chronic pancreatitis. Harrison's Online. Available from:http://www.accessmedicine.com. [accessed on 2006 May 31]3. Chari ST, Vege SS. Etiology of acute pancreatitis. Up-to-date. Available from: http://www.uptodate.com. [accessed on 2006 May 31]4. Hunter TB, Bjelland JC. Gastrointestinal complications of leukemia and its treatment. AJR Am J Roentgenol. 1984;142:513–8. [PubMed]5. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH. Drug-associated acute pancreatitis: Twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol. 1999;94:2417–22. [PubMed]
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Articles |
| Authors | |
| Publication Date | April 30, 2020 |
| Submission Date | March 5, 2019 |
| Acceptance Date | January 16, 2020 |
| Published in Issue | Year 2020 Volume: 13 Issue: 1 |
Cite
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.
This work is licensed with Attribution-NonCommercial 4.0 International.